APG-1387 is under clinical development by Ascentage Pharma Group International and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase I drugs for Metastatic Pancreatic Cancer have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how APG-1387’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APG-1387 is under development for the treatment of advanced solid tumor including nasopharyngeal carcinoma, advanced pancreatic ductal adenocarcinoma, advanced non-small cell lung cancer, colorectal cancer, blood cancer, pancreatic cancer, peritoneal carcinomatosis (peritoneal cancer) and hepatitis B. It was under development for the treatment of head and neck cancer, leukemia and lymphoma. The drug candidate is a new chemical entity administered through intravenous and parenteral route. The drug candidate acts by targeting (IAP) inhibitor of apoptosis protein.
Ascentage Pharma Group International overview
Ascentage Pharma Group International (Ascentage Pharma) is a biotechnology company that discovers and develops targeted small-molecule therapies for the treatment of cancer, hepatitis B and age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company product pipeline includes HQP8361, APG-2449, APG-2575, APG-1252, APG-115, APG-1387, APG-5918, APG-265, AS1266 and UBX1967/1325. Ascentage Pharma lead candidate HQP8361 is a second-generation c-Met kinase inhibitor for the treatment of c-Met positive cancers, gastric cancer, non-small cell lung cancer and liver cancer. It operates research and development centers and production facilities in Hong Kong, China, and the US. Ascentage Pharma is headquartered in Suzhou, Jiangsu, China.
For a complete picture of APG-1387’s drug-specific PTSR and LoA scores, buy the report here.